There have been significant developments in the treatment of Feline Infectious Peritonitis (FIP) across the EU. One of the most notable changes is the availability of extemporaneous products containing GS-441524 in France, offered by manufacturers such as Pharmacy Delpech and FrancePrep (BOVA formula). These products provide veterinarians with a legal, regulated option to treat FIP. This is a crucial development, as the unavailability of an authorized GS-441524 product in EU previously led using the black market to access the drug.
Additionally, emerging research suggests that the treatment duration may be significantly reduced, potentially halving the previous 84-day protocol to just 42 days, making treatment more accessible and less burdensome for pet owners.
Recap of the Webinar
On July 4th, FVE and the Federation of European Companion Animal Veterinary Associations (FECAVA) hosted a joint-joint webinar on the challenges and opportunities of Feline Infectious Peritonitis (FIP) treatment. The webinar gathered scientists, practitioners, competent authorities, pharmaceutical industry and policymakers alike.
Read our summary brochure on FIP treatment options within the EU and beyond HERE! Check out the highlights in the webinar report HERE and watch the recording of the webinar HERE.
- Keynote speaker Professor Katrin Hartmann (Ludwig Maximilians University Munich, Germany) recapped the current knowledge on the different antiviral treatments with a special emphasis on animal trials of the GS-441524. Her presentation is HERE.
- Emma Jones (BOVA Specials UK) highlighted the GMP-compliant production of extemporaneous FIP treatments, which adhere to strict quality controls. Her presentation is HERE.
- Dr. Sam Taylor (International Society of Feline Medicine) shared international perspectives on FIP treatment. Her presentation is HERE.
Evolving Treatment Landscape
With extemporaneous GS-441524 products now legally available in France and research pointing to shorter treatment durations, FIP treatment options are steadily improving. However, as of now, no pharmaceutical company has officially sought approval for a GS-441524 product, meaning that most treatment remains dependent on extemporaneous preparations.
Take home messages
-
We highly recommend continuous monitoring of FIP prevalence on the national level!
-
We advocate policymakers to harmonize regulations so veterinarians have access to safe and effective FIP treatments while they support cat owners through this challenging process!
